anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
New replication-defective adenoviruses are selected from: (a) those that are derived from a natural adenovirus and lack at least the coding sequences of the E1B region and/or at least part of the E4 region; (b) those that are derived from a natural adenovirus other than a human type 5 adenovirus (Ad5) and lack part of the encapsidation region; (c) those that are derived from Ad5 and lack the part of the encapsidation region corresp. to nucleotides 270-346 in the Genbank M73260 sequence; and (d) those that are derived from Ad5 and lack the part of the encapsidation region corresp. to nucleotides 184-273 in the Genbank M73260 sequence. Also claimed is a eukaryotic cell contg. an adenovirus as above. Also claimed are: (1) a complementation line comprising a cell line contg. a complementation element which comprises at least part of the E1 region of a natural adenovirus and lacks the 5&#39; ITR sequence, the element being integrated into the genome or inserted into a vector: and (2) a process for producing a defective adenovirus as above, comprising introducing the virus into a complementation line as above, culturing the cell line, and recovering the virus from the culture supernatant.
PURPOSE:To obtain the titled dispersion liquid obtained by dividing an oil or fat into fine particles having a specific average diameter and dispersing the particles uniformly in an aqueous solution of gelatin. CONSTITUTION:Finely divided particles of an oil or fat (e.g. liquid paraffin, cottonseed oil, soybean oil, coconut oil, cacao fat, etc.) having an average parti cle diameter of &lt;=10mum, preferably &lt;=0.2mum are dispersed uniformly in an aque ous solution of gelatin (an O/W-type emulsion containing 15-30wt% gelatin) to obtain the objective dispersion liquid for hard gelatin capsule. The amount of the oil or fat dispersed in the emulsion is 1-20wt%. The concentration of gelatin is preferably about 27wt% when the dispersion is used as a base for forming a capsule and is preferably about 22wt% when the dispersion is used as a band sealing liquid. EFFECT:The capsule produced by the use of the above liquid is resistant to crack generation and has remarkably improved moisture-permeability, solubility, disintegrability, appearance, gloss, etc. Various capsules having different colors can be produced by combining other color pigments.
Pyrrolo[2,1-b]-3-benzazepines of the formula &lt;IMAGE&gt; and their salts, e.g. cis/trans geometrical isomers, are prepared in pure form or as mixture. The substituents are defined in Claim 1. These compounds are obtained by reacting an appropriate aldehyde compound, namely an 11-(3-oxopropylidene) derivative with ammonia or an appropriate amine in the presence of a reducing agent. The isomers, preferably the E isomer, can be obtained from the mixture of isomers by chromatographic separation. The resulting compounds can be used as skeletal muscle relaxants or sedatives.
FIELD: medicinal biotechnology, microbiology, vaccines. SUBSTANCE: invention can be used for preparing vaccine against leptospirosis. The strain L. interrogans is isolated from patient blood with leptospirosis. The strain heated at 56 C for 1 h elicits high immunogenic activity and protects experimental animals from death in administration to them of virulent leptospira in the dose that exceeds the lethal dose by 100-fold. Serum of animals immunized with experimental vaccine samples prepared from the strain &#34;Mitronov&#34; and containing antibodies raised against to leptospira of serum group Canicola exhibits high protective effect in experiment in golden hamster: ED 50  = 0.2. The strain is deposited in the collection NIIEM named for Hamalea AMS RF at = 480. Using the strain L. interragans = 480 provides preparing vaccine against epidemiologically actual pathogen of leptospirosis. EFFECT: valuable properties of strain and vaccine.
Systems and methods for cancer subject tumor fraction estimation comprise obtaining a first plurality of nucleic acid fragment sequences from the subject&#39;s liquid biological sample. The first plurality of sequences represent cell-free nucleic acids in the liquid sample. A second plurality of nucleic acid fragment sequences is obtained from the subject&#39;s tumor sample. The second plurality of sequences represent nucleic acid molecules in the tumor. Smoothed noise rates, each determined using nucleic acid fragment sequences from non-cancer samples mapping to a corresponding allele position in a plurality of allele positions, are obtained. Variant allele counts and coverages are determined for the allele positions using the first plurality of sequences. Solid variant allele fractions are determined for the plurality of allele positions using the second plurality of sequences. The subject tumor fraction is calculated using the smoothed noise rates, variant allele counts, coverages, and solid variant allele fractions.
Orally administrable granules comprise paraaminosalicylic acid or its salts or esters embedded in a fat.  Isonicotinic acid hydrazide and conventional binders, e.g. water-soluble starch or cellulose derivatives may optionally be included.  The granules, which may optionally be coated, e.g. with shellac, sugar or cellulose derivatives may be prepared by mixing together the active material and fat, adding the binder and moulding the mixture into &#34;strings&#34; which are broken up into substantially cylindrical granules, e.g. by cutting or crushing followed, if desired, by coating by conventional means with conventional enteric coatings, e.g. of shellac or cellulose derivatives.  The preferred fat is lard.  Others which may be used are synthetic glycerides of fatty acids (preferably of single acids) and other natural fats, e.g. whale or coconut oil which may be hardened by hydrogenation.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an immunological reagent used for treatments in radiation immunotherapy (RAIT) and immunochemotherapy and an immunological reagent used for detection and/or diagnosis in radiation-immunity detection (RAID), ultrasonic examination and magnetic resonance imaging (MRI).  &lt;P&gt;SOLUTION: A bi-specific antibody or antibody fragment having at least one arm able to react with a targeted tissue and at least one other arm able to react with a linker moiety is provided. The linker moiety contains a hapten in which an antibody is prepared. Such an antigenic linker is conjugated with one or more therapeutic agents, diagnostic agents or enzymes. A construct and a method for producing the bi-specific antibodies or antibody fragments are provided. A method for using the same is also provided.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an aqueous composition comprising brinzolamide being completely dissolved therein.  &lt;P&gt;SOLUTION: The aqueous composition is composed, in an aqueous solution, of brinzolamide and a polycarboxylic acid or its pharmaceutically acceptable salt, an acid saccharide or its pharmaceutically acceptable salt and/or a mucopolysaccharide or its pharmaceutically acceptable salt. The aqueous composition is predicted to alleviate blurred vision on administration better than a conventional suspension ophthalmic solution to be expected for patients to use easier. In addition, it is expected that the production cost is reduced since the composition is completely dissolved so that the production is not complicated on the contrary that the production of the suspension ophthalmic solution needs complicated equipment. Further, the securement of sterility is expected to be easy.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
PURPOSE:To provide a black liquid cosmetic containing a titanium oxynitride having a diameter smaller than a specific level and a specific liquid humectant such as propylene glycol as essential components, having excellent line-drawing performance, applicability and safety and suitable as a pen-type cosmetic tool. CONSTITUTION:A titanium oxynitride containing 4-35wt% oxygen and 2-20wt% nitrogen and having particle diameter of &lt;=1mum is used as a colorant of the objective black liquid cosmetic having a viscosity of 1.5-200cps. The cosmetic contains the above colorant and one or more compounds selected from propylene glycol, glycerol, polyethylene glycol and 1,3-butylene glycol as essential components. The amount of the glycol, etc., is 2-30wt% based on the colorant. Since the colorant is free from harmful substance, the obtained cosmetic is safe. The dispersion stability of the cosmetic is high because the colorant is non-magnetic. Furthermore, since the cosmetic has low viscosity and excellent applicability, it can be applied smoothly from the applicator without causing clogging when used as a pen-type cosmetic tool such as eyeliner.
This invention relates to a novel method for the delivery of cytotoxic drugs to tumor cells by the administration of a tumor-specific antibody-enzyme conjugate that binds to the tumor cells, and the additional administration of a prodrug that is converted at the tumor site, in the presence of the antibody-bound enzyme, to an active cytotoxic drug. According to preferred embodiments of this invention, antibody-enzyme conjugates containing the enzyme, alkaline phosphatase (&#34;AP&#34;), have been used in conjunction with the novel prodrug, etoposide-4′-phosphate or 7-(2′-aminoethyl phosphate)mitomycin or a combination thereof, to effect killing of tumor cells. According to another embodiment of the invention, an antibody-enzyme conjugate containing the enzyme, penicillin V amidase (&#34;PVA&#34;), has been used. in conjunction with a novel prodrug, N-( p -hydroxyphenoxyacetyl)adriamycin to effect killing of tumor cells. Still another embodiment of the invention relates to the use of an antibody-enzyme conjugate containing the enzyme, cytosine deaminase (&#34;CD&#34;), in combination with the prodrug, 5-fluorocytosine, to effect killing of tumor cells. The methods, antibody-enzyme conjugates, prodrugs, pharmaceutical compositions and combinations of this invention provide for enhanced selective killing of tumor cells and are thus useful in the treatment of cancers and other tumors.
PURPOSE:To purify a substance containing erythropoietin, particularly a urine, blood plasma, biological sample solution, etc., by using a carrier containing a combined anthraquinone compound. CONSTITUTION:An anthraquinone compound, e.g. a compound of formula I , formula II or formula III, etc. is combined with an insoluble high polymer carrier, e.g. a synthetic high polymer carrier such as nylon or cellulose acetate, etc. of natural high polymer carrier such as peptide, e.g. silk, or polysaccharide, e.g. cellulose, to give a carrier containing the combined anthraquinone compound. The resultant carrier is then brought into contact with a substance containing erythropoietin, e.g. urine or blood plasma of a patient with hypoplastic anemia or urine or blood plasma of an animal with hemolytic anemia, at 3-11pH and &lt;=0.5M ionic strength with NaCl and 0-50 deg.C conditions. The resultant substance is washed fully with a phosphoric acid buffer physiological saline solution and then eluted with an eluant, e.g. guanidine hydrochloride solution to give the aimed erythropoietin of high purity.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a composition for the treatment of ageing skin and the delaying of the onset of the signs of ageing in healthy skin.  &lt;P&gt;SOLUTION: The composition comprises cartilage extract, grape seed extract, and tomato extract with marked antioxidant effect and free-radical inhibition. The composition, comprising a hydrophilic antioxidant, a lipophilic (hydrophobic) antioxidant, and a cartilage extract, dramatically increases collagen synthesis in the dermis. Furthermore, the composition reduces collagenase activity and level of advanced glycosylation end product (AGE). The composition is intended for the treatment of ageing skin and the delaying of the onset of the signs of ageing in healthy skin.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
The present invention provides a kind of Chinese medicine preparation treating pig endoparasite and preparation method thereof, relates to technical field of traditional Chinese medicine preparation.The primary raw material of described Chinese medicine preparation consists of: Fructus Quisqualis, Aloe, Semen Arecae, Semen Pharbitidis, Herba Anemones Hupehensis, Cortex Alchorneae Davidii, Viburnum dilatatum Thunb. flower, G1ycosmis Pentaphylla (Retz) Correa. (G1ycosmis arborea (Roxb.)DC.), Fructus Styracis obassiae, Radix Myrsines semiserratae, Folium fici wightianae (Ficus wightiana Wall), lysimachia ramosa Wall, Medinilla Denstita Rexb., Rhizoma weed, Caulis wisteriae sinensis, Baliospermum micrxnthum muell Arg, Digenea simplex (Wnlf.) C. Ag., Lysimachia tengyuehensis Hand-Mazz, Folium Stevlae Rebaudianae and Radix Glycyrrhizae.The each crude drug of the present invention, through scientific compatibility, synergism, has heat-clearing and toxic substances removing, killing insect and eliminating accumulation, the effects such as spleen benefiting and stimulating the appetite, not only for the adult good effect in pig body, directly driving property is strong, but also the worm&#39;s ovum of not yet adult can be killed, instant effect, short treating period, cure rate is high, have no side effect, be worthy of popularization.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a lip cream containing a base material for the lip cream and a tacky/adhesive agent of 5-200 pts.wt. per 100 pts.wt. of the base material.  &lt;P&gt;SOLUTION: The lip cream which keeps the lips closed and facilitates breathing through the nose is obtained by the lip cream containing the base material 100 for the lip cream and the tacky/adhesive agent of 5-200 pts.wt. per 100 pts.wt. of the base material. Since the lip cream shows the appropriate stickiness, the lips are kept closed easily if the lip cream is applied to the lips when sleeping or going out. Consequently, air is breathed mainly through the nose, and the dryness of the mucous membranes from the inside of the oral cavity to the windpipe is prevented.  &lt;P&gt;COPYRIGHT: (C)2004,JPO&amp;NCIPI
The present invention relates to the field of food technology, disclosing a rich-in-Se fresh flower paste with high nutrient value and its preparation method. It&#39;s prepared from using seleniferous black soybeans, maize flower pistils, garlics, onions, edible flowers as raw materials, mixed with white sugar and malic acid, and their proportioning is 2.5-3.5:1:0.8-1.3:0.06-0.08. The edible flowers may be loofah flowers, pumpkin flowers, waxgourd flowers, camellias, bombax flowers, pagodatree flowers, pear flowers, plum blossom, peach blossom, China rose ,rose and so on. Malic acid can be replaced by citric acid. It can promote metabolism and delays senility. For adding selenium, it can prevent cancer and reduce incidence of cancer.
The present invention is related to the fields of drug delivery and implantable devices. Devices, systems, and methods for use of drug delivery implants are contemplated herein. The present invention relates to implantable devices, as well as their methods of use and manufacturing. Exemplary embodiments of the present invention include fiber and sheet based implantable devices for drug delivery to bodily lumens. In particular, implantable drug delivery device compositions are contemplated for use providing consistent drug delivery over time to the central nervous system for treating associated disorders and disease. As one specific example, a CNS delivery device is contemplated for implantation in a region of the nose for providing consistent drug delivery over time to brain tissue for treating brain associated diseases, e.g. Alzheimer&#39;s disease (AD) and related dementias (AD/ADRD).
The present invention belongs to the technical field of genetic engineering for producing polypeptide drugs in the biotechnology pharmaceutical industry. A domestic silkworm larvae, a pupa and a moth are used as bioreactors, a recombinant domestic silkworm nuclear polyhydrosis virus with human erythropoietin genes is obtained by recombination in the domestic silkworm cells by using a domestic silkworm nuclear polyhydrosis virus expression system through the genetic engineering technology, and is expressed by the inoculation of the domestic silkworm larvae, the pupa and the moth. The magnitude of an expression product is approximately from 25 to 27 KD; a pure product is obtained through separation and purification; injections whose activity is 10&lt;8&gt;unit /mg is obtained through freeze-drying. The expression product is freeze-dried to be manufactured into oral taking capsules after ultrasonic treatment. An animal experiment proves that the injection and the oral taking capsule medicine have unambiguous effect of generating red blood cells. The invention of production and recombination of human erythropoietin injection medicine and oral taking medicine by using the domestic silkworm is realized for the first time. Compared with the prior art, the preparation method in the present invention has the advantages of easy acquirement of raw materials, low production cost, good medicine effect, particularly good oral taking effect and important implement value.
A process for the production of a dental prosthesis comprises disposing a paste or viscous solution which polymerizes at room temperature or a slightly elevated temperature between a model and a base plate, pressing the base plate so that the paste or solution fills all the interstices between the base plate and the model and allowing the paste or solution to polymerize to form a lining on the base plate.  A model is prepared after taking an impression of the jaw.  The base plate is cut to the shape of the model from a sheet of suitable synthetic resin material.  The base plate is softened by boiling water and shaped to the model, the shape being made permanent by immersing in cold water.  A suitable lining mixture is then applied to the tissue side of the base plate which is then pressed on the model so that the mixture fills the interstices between the base plate and the model.  The lining mixture polymerizes at room temperature in a short time. Teeth of porcelain or polymethyl methacrylate are affixed to the plate using the same mixture as for the lining.  The polymerized parts require finishing and polishing. In cutting the base plate a pattern in tin foil cut to the model may be used.  In shaping the base plate to the model the hands may be protected from the heat by placing a foil of cellulose acetate over the base plate. The plastic mixture may be shaped in the mouth of the patient which is protected by greasing with &#34;Vaseline&#34; (Registered Trade Mark).  The base plate is made of copolymers of methyl methacrylate and butadiene or its derivatives, methyl methacrylate or vinyl chloride and acrylates or methacrylates the alcohol radical of which contains more than three carbon atoms or polymethyl methacrylate plasticized with benzyl-butyl adipate or suitable phthalates.  The lining mixture is made from mixtures or viscous solutions of polymeric and monomeric vinyl compounds such as polymeric and monomeric methacrylate or solutions of polymethyl methacrylate in methyl methacrylates containing Redox systems. Styrene, acrylonitrile or compounds having at least two polymerizable double bonds, e.g. divinyl benzene or ethylene glycol dimethacrylate or polyfunctional vinyl compounds may be added to the materials of the base plate.  Specification 558,470 is referred to.
PROBLEM TO BE SOLVED: To provide an improved treatment of a cancer such as melanoma, glioma of a high grade malignancy, lung cancer and mammary cancer by administrating temozolomide in one or more times per day. SOLUTION: This improved treatment for a cancer comprises administrating temozolomide of the formula (i.e., 3,4-dihydro-3-methyl-4-oxoimidazo-[5,1-d]1,2,3,4- tetrazine-8-carboximide) in one or more times per day. The total dose of 500-1,200mg/m&lt;2&gt; body surface of a patient is administrated during 5 days by dividing the dose. In the case of the total dose of 1,000mg/m&lt;2&gt; , the daily dose becomes 200mg/m&lt;2&gt; . The daily dose is preferably administrated in 2-4 divided doses. The temozolomide is preferably administered again after 28 days from the first dose. The temozolonide can be administered in a smaller amount for a long period. In this case, the daily dose of 75mg/m&lt;2&gt; is preferably continued for 6 weeks. Moreover, regardless of a dosing period or a total amount of dose, a large amount of an oral pill is preferably administered at the first dose.
The invention discloses a micro-filtration and ultra-filtration combined efficient green purification technology for ganoderma lucidum polysaccharide. A ganoderma lucidum polysaccharide solution extracted by ultrasonic is used as an experimental material, and the extract is micro-filtered with meshes of 0.2 micron to remove impurities such as organic colloid and mechanical particles. The micro-filtered permeate is ultra-filtered, the liquid is delivered to the surface of a membrane (50kDa and the area of the membrane is 0.1m&lt;2&gt;) by a peristaltic pump to flow tangentially, the filtrate is collected, and the intercepted liquid is refluxed to a liquid storage tank; when the liquid is concentrated to about one fourth of volume, the ultra-filtration process is finished; and (95 percent) ethanol in a volume which is 4 times that of the liquid is used for precipitation, freeze-drying and weighing are carried out. The experimental conditions comprise that the temperature is 35 DEG C; in the operating pressure, the inlet pressure is 0.82bar, and the outlet pressure is 0.68bar; and the trans-membrane pressure difference delta P is equal to (0.82+0.68)/2 and equal to 0.75bar. The purity of the ultra-filtered ganoderma lucidum polysaccharide reaches 61.32 percent, and concentration and purification processes of the ganoderma lucidum polysaccharide are greatly simplified. The obtained ganoderma lucidum polysaccharide can be widely applied to a base material for medicaments and health-care food.
PURPOSE:The titled remedy extremely effective for milch cows, showing excellent recovering action on ketosis causing lack of appetite, reduction in weight, symptoms of deterioration in milk quality of domestic animals, especially cattle, containing a dithia compound as an active ingredient. CONSTITUTION:The titled remedy containing a dithia compound such as diisopropyl 1,3-dithiolan-2-inden malonate, or diisopropyl 1,3-dithiol-2-inden malonate shown by the formula I [R and R&#39; are lower alkyl; n is 0-2; A is CH2, group shown by the formula II (M is H, or salt-forming group), CH=CH, CH2CH, etc.] as an active ingredient. When the active ingredient is applied to domestic animals, the active ingredient is administered alone or in the form of powder, etc. A dose is 0.1-250mg, preferably 1-100mg based on 1kg.wt. daily in the case of oral administration, and preferably 0.01-250mg in the case of parenteral administration.
This invention is directed to novel purine-based compounds for inclusion into oligonucleotides. The compounds of the invention, when incorporated into oligonucleotides are especially useful as &#34;antisense&#34; agents -- agents that are capable of specific hybridization with a nucleotide sequence of an RNA. The compounds of the invention may also be used for cross-linking oligonucleotides. Oligonucleotides are used for a variety of therapeutic and diagnostic purposes, such as treating deseases, regulating gene expression in experimental systems, assaying for RNA and for RNA products through the employment of antisense interactions with such RNA, diagnosing diseases, modulating the production of proteins, and cleaving RNA in site specific fashions. The compounds of the invention include novel heterocyclic bases, nucleosides, and nucleotides. When incorporated into oligonucleotides, the compounds of the invention can be useful for modulating the activity of RNA.